Galectin Therapeutics Inc. (NASDAQ:GALT) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 4,478,900 shares, an increase of 18.0% from the June 15th total of 3,796,800 shares. Currently, 13.0% of the shares of the company are sold short. Based on an average trading volume of 376,300 shares, the short-interest ratio is presently 11.9 days.

Several brokerages have commented on GALT. ValuEngine lowered Zymeworks from a “buy” rating to a “hold” rating in a report on Saturday, May 18th. Zacks Investment Research raised Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Tuesday, July 16th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Galectin Therapeutics has a consensus rating of “Buy” and an average price target of $9.17.

In related news, Director Richard E. Uihlein bought 4,680,606 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The shares were purchased at an average cost of $4.28 per share, with a total value of $20,032,993.68. Following the completion of the acquisition, the director now directly owns 3,128,489 shares in the company, valued at $13,389,932.92. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 45.20% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the company. BlackRock Inc. lifted its position in Galectin Therapeutics by 0.4% during the fourth quarter. BlackRock Inc. now owns 604,268 shares of the company’s stock worth $2,073,000 after buying an additional 2,611 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in Galectin Therapeutics by 25.1% during the second quarter. Commonwealth Equity Services LLC now owns 15,247 shares of the company’s stock worth $63,000 after buying an additional 3,059 shares in the last quarter. MML Investors Services LLC lifted its position in Galectin Therapeutics by 55.8% during the fourth quarter. MML Investors Services LLC now owns 26,926 shares of the company’s stock worth $92,000 after buying an additional 9,642 shares in the last quarter. WINTON GROUP Ltd lifted its position in Galectin Therapeutics by 37.5% during the second quarter. WINTON GROUP Ltd now owns 40,279 shares of the company’s stock worth $167,000 after buying an additional 10,986 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Galectin Therapeutics by 7.3% during the fourth quarter. Geode Capital Management LLC now owns 227,175 shares of the company’s stock worth $779,000 after buying an additional 15,410 shares in the last quarter. 15.88% of the stock is currently owned by hedge funds and other institutional investors.

GALT traded up $0.09 during trading on Friday, hitting $3.80. The company’s stock had a trading volume of 226,892 shares, compared to its average volume of 410,351. Galectin Therapeutics has a twelve month low of $3.17 and a twelve month high of $6.98. The business’s fifty day moving average price is $3.92. The company has a market cap of $173.24 million, a price-to-earnings ratio of -10.00 and a beta of 3.16.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.06. As a group, analysts anticipate that Galectin Therapeutics will post -0.45 earnings per share for the current year.

About Galectin Therapeutics

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

See Also: Stop Order Uses For Individual Investors

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.